Creative Planning
SYRE icon

Creative Planning’s Spyre Therapeutics SYRE Stock Holding History

Creative Planning’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.28M Buy
25,713
+10,227
+66% +$746K ﹤0.01% 1973
2026
Q1 		$781K Buy
+15,486
New +$584K ﹤0.01% 2662

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Creative Planning's SYRE Position: Q2 2026 in Review

Creative Planning increased its Spyre Therapeutics (SYRE) stake by 66% in Q2 2026, buying an estimated $746K and bringing the position to 25,713 shares worth $2.28M. The position accounts for ﹤0.01% of the portfolio, ranked #1973.

Creative Planning first reported a position in SYRE in Q1 2026 and has held it in 2 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Creative Planning held 25,713 shares of Spyre Therapeutics worth $2.28M as of Q2 2026.
  • Creative Planning bought 10,227 Spyre Therapeutics shares in Q2 2026, an estimated $746K.
  • Spyre Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #1973 holding.
  • Creative Planning first reported a position in Spyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.